the specific foreign-status material(s)/component(s) and specific finished product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website—accessible via *www.trade.gov/ftz.*

The proposed finished products include: Incretin-based therapy for blood glucose and weight management drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; CGRP monoclonal antibody for migraine prevention drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi finished syringes; IL–17A monoclonal antibody for chronic inflammatory conditions drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; Incretin-based therapy for blood glucose management in type 2 diabetes drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; Multi-incretin therapy for weight and metabolic management drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; IL–13–targeted therapy for atopic dermatitis management drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi finished syringes; IL–23–targeted therapy for inflammatory bowel disease management drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; Amylin receptor-targeted therapy for weight management drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; and Amyloid-targeted therapy for early Alzheimer's disease drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes (duty free).

The proposed foreign-status materials/components include: Incretin-based therapy for blood glucose and weight management drug substance; Incretin-based therapy for blood glucose and weight management drug product in vials or semi-finished syringes; CGRP monoclonal antibody for migraine prevention drug substance; CGRP monoclonal antibody for migraine prevention drug product in vials or semi-finished syringes; IL–17A monoclonal antibody for chronic inflammatory conditions drug substance; IL–17A monoclonal antibody for chronic inflammatory conditions drug product in vials or semi-finished syringes; Incretin-based therapy for blood glucose management in type 2 diabetes drug substance; Incretin-based therapy for blood glucose management in type 2 diabetes drug product in vials or semi-finished syringes; Multi-incretin therapy for weight and metabolic management drug substance; Multi-incretin therapy for weight and metabolic management drug product in vials or semi-finished syringes; IL–13–targeted therapy for atopic dermatitis management drug substance; IL–13–targeted therapy for atopic dermatitis management drug product in vials or semi-finished syringes; IL–23–targeted therapy for inflammatory bowel disease management drug substance; IL–23–targeted therapy for inflammatory bowel disease management drug product in vials or semi-finished syringes; Amylin receptor-targeted therapy for weight management drug product in vials or semi-finished syringes; Amylin receptor-targeted therapy for weight management drug substance; Amyloid-targeted therapy for early Alzheimer's disease drug product in vials or semi-finished syringes; Amyloid-targeted therapy for early Alzheimer's disease drug substance; Medicine delivery device, and parts thereof—including Cap Cartridge Holder, Dry Side Subassembly, Damping Cup, RNS Puller, Base Cap; Medicine delivery device needles; Glass vials; and Syringes (duty free).

The request indicates that certain materials/components are subject to duties under section 232 of the Trade Expansion Act of 1962 or section 301 of the Trade Act of 1974, depending on the country of origin. The applicable section 232 and section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status as described in 19 CFR 146.41.

Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: *ftz@trade.gov.* The closing period for their receipt is November 4, 2026.

A copy of the notification will be available for public inspection in the ''Online FTZ Information System'' section of the Board's website.

For further information, contact John Frye at *John.Frye@trade.gov.*

Dated: September 22, 2026.

Colin Agostisi,

Executive Secretary.

[FR Doc. 2026–19699 Filed 9–24–26; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B–122–2026]

Foreign-Trade Zone (FTZ) 93, Notification of Proposed Production Activity; Eli Lilly and Company; (Drug Products); Durham, North Carolina

Eli Lilly and Company submitted a notification of proposed production activity to the FTZ Board (the Board) for its facility in Durham, North Carolina within Subzone 93K. The notification conforming to the requirements of the Board's regulations (15 CFR 400.22) was received on September 17, 2026.

Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material(s)/component(s) and specific finished product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website—accessible via *www.trade.gov/ftz.*

The proposed finished products include: Incretin-based therapy for blood glucose and weight management drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; CGRP monoclonal antibody for migraine prevention drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi finished syringes; IL–17A monoclonal antibody for chronic inflammatory conditions drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; Incretin-based therapy for blood glucose management in type 2 diabetes drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; Multi-incretin therapy for weight and metabolic management drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; IL–13–targeted therapy for atopic dermatitis management drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi finished syringes; IL–23–targeted therapy for inflammatory bowel disease management drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; Amylin receptor-targeted therapy for weight management drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes; and Amyloid-

targeted therapy for early Alzheimer's disease drug product in dosage/packaged form in filled syringes, vials, or delivery pens or semi-finished syringes (duty free).

The proposed foreign-status materials/components include: Incretin-based therapy for blood glucose and weight management drug substance; Incretin-based therapy for blood glucose and weight management drug product in vials or semi-finished syringes; CGRP monoclonal antibody for migraine prevention drug substance; CGRP monoclonal antibody for migraine prevention drug product in vials or semi-finished syringes; IL–17A monoclonal antibody for chronic inflammatory conditions drug substance; IL–17A monoclonal antibody for chronic inflammatory conditions drug product in vials or semi-finished syringes; Incretin-based therapy for blood glucose management in type 2 diabetes drug substance; Incretin-based therapy for blood glucose management in type 2 diabetes drug product in vials or semi-finished syringes; Multi-incretin therapy for weight and metabolic management drug substance; Multi-incretin therapy for weight and metabolic management drug product in vials or semi-finished syringes; IL–13–targeted therapy for atopic dermatitis management drug substance; IL–13–targeted therapy for atopic dermatitis management drug product in vials or semi-finished syringes; IL–23–targeted therapy for inflammatory bowel disease management drug substance; IL–23–targeted therapy for inflammatory bowel disease management drug product in vials or semi-finished syringes; Amylin receptor-targeted therapy for weight management drug product in vials or semi-finished syringes; Amylin receptor-targeted therapy for weight management drug substance; Amyloid-targeted therapy for early Alzheimer's disease drug product in vials or semi-finished syringes; Amyloid-targeted therapy for early Alzheimer's disease drug substance; Medicine delivery device, and parts thereof—including Cap Cartridge Holder, Dry Side Subassembly, Damping Cup, RNS Puller, Base Cap; Medicine delivery device needles; Glass vials; and Syringes (duty free).

The request indicates that certain materials/components are subject to duties under section 232 of the Trade Expansion Act of 1962 or section 301 of the Trade Act of 1974, depending on the country of origin. The applicable section 232 and section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status as described in 19 CFR 146.41.

Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: *ftz@trade.gov.* The closing period for their receipt is November 4, 2026.

A copy of the notification will be available for public inspection in the ''Online FTZ Information System'' section of the Board's website.

For further information, contact John Frye at *John.Frye@trade.gov.*

Dated: September 22, 2026.

Colin Agostisi,

Executive Secretary.

[FR Doc. 2026–19698 Filed 9–24–26; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

International Trade Administration

[A–580–914]

Certain Superabsorbent Polymers From the Republic of Korea: Final Results of Antidumping Duty Administrative Review; 2023–2024

AGENCY: Enforcement and Compliance, International Trade Administration, Department of Commerce.

DATES: Applicable September 25, 2026.

SUMMARY: The U.S. Department of Commerce (Commerce) determines that certain superabsorbent polymers (SAP) from the Republic of Korea (Korea) were not sold in the United States at less than normal value (NV) during the period of review (POR), December 1, 2023, through November 30, 2024.

FOR FURTHER INFORMATION CONTACT: Charles DeFilippo, AD/CVD Operations, Office VII, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482–3797.

SUPPLEMENTARY INFORMATION:

Background

On May 22, 2026, Commerce published in the **Federal Register** the *Preliminary Results* of the 2023–2024 administrative review of the antidumping duty order on SAP from Korea and invited interested parties to comment.[1] We received no comments from interested parties on the *Preliminary Results.* Accordingly, we made no changes to the *Preliminary Results,* and thus, no decision memorandum accompanies this notice. Commerce conducted this administrative review in accordance with section 751(a) of the Tariff Act of 1930, as amended (the Act).

Scope of the Order [2]

The merchandise subject to the *Order* is SAP. For a full description of the scope, *see* the *Preliminary Results* PDM.

Final Results of Review

In the *Preliminary Results,* we determined that LG Chem, Ltd. (LGC) did not make sales of subject merchandise at less than NV during the POR. As noted above, Commerce received no comments concerning the *Preliminary Results.* Therefore, for these final results, we continue to determine the below final weighted-average dumping margin exists for the period December 1, 2023, through November 30, 2024:

Producer/exporter	Weighted-average dumping margin (percent)
LG Chem, Ltd	0.00

Disclosure

Normally, Commerce discloses to interested parties the calculations of the final results of an administrative review within five days of a public announcement or, if there is no public announcement, within five days of the date of publication of the final results in the **Federal Register**, in accordance with 19 CFR 351.224(b). However, because we have made no changes from the *Preliminary Results,* there are no calculations to disclose.

Assessment Rates

Pursuant to section 751(a)(2)(C) of the Act, and 19 CFR 351.212(b)(1), Commerce has determined, and CBP shall assess, antidumping duties on all appropriate entries of subject merchandise in accordance with the final results of this review. Because we calculated a zero percent margin in the final results of this review for LGC, in accordance with 19 CFR 351.212, we will instruct CBP to liquidate the appropriate entries without regard to antidumping duties.

[1] *See Certain Superabsorbent Polymers from the Republic of Korea: Preliminary Results of Antidumping Duty Administrative Review; 2023–2024,* 91 FR 30278 (May 22, 2026) (*Preliminary Results*), and accompanying Preliminary Decision Memorandum (PDM).

[2] *See Certain Superabsorbent Polymers from the Republic of Korea: Notice of Court Decision Not in Harmony With the Final Determination of Antidumping Duty Investigation; Notice of Amended Final Determination; Notice of Amended Antidumping Duty Order,* 90 FR 302 (January 3, 2025) (*Order*).